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INTRODUCTION 
Together with the progressive disability secondary to the joint impairment, 
cardiovascular (CV) risk is a major issue in patients with rheumatic diseases, 
such as Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).[1] In this 
clinical settings, a high prevalence of the metabolic syndrome and of its major 
features (obesity, hypertension, impaired fasting glucose, 
hypercholesterolemia, hypertriglyceridemia) has been described.[2] However, 
such an association does not entirely explain the extent of premature 
atherosclerosis in rheumatic subjects and inflammation appears to act 
synergistically with traditional vascular risk factors (VRFs), thus contributing 
to the atherosclerotic process and to the increased CV risk.[3,4] Monocytes, 
CD4+ T-lymphocytes and most pro-inflammatory cytokines (Tumor Necrosis 
Factor-α [TNF-α], interleukin [IL]-1β, IL-6 and IL-18), play a central role in 
the pathophysiology of major arthritides,[5] and are involved in the induction 
and in the maintenance of the atherosclerotic process (hyperlipidemia, 
insulin-resistance, adhesion of white cells to endothelium, over-expression of 
some molecules, “fatty streaks” formation and atherosclerotic plaque 
progression and rupture).[6,7,8] On the other hand, VRFs may play a role in the 
development of inflammation. For instance, being associated with the 
production of “adipokines” (TNF-α, IL-6, leptin, adiponectin), obesity causes a 
pro-inflammatory status.[9,10,11]  
In the last years a growing interest has been devoted to the evaluation of the 
complex interplay among these mechanisms, to better address the issue of CV 
mortality and morbidity in rheumatic patients. Most of available studies have 
been conducted on patients with RA, a systemic, autoimmune disorder 
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characterized by synovial inflammation of multiple joints and by an higher 
than normal prevalence of co-morbidities.[12]  
As to CV morbidity and mortality in RA, according to a meta-analysis of 24 
observational studies (111,758 RA patients, 22,927 CV events), mortality 
risks for ischemic heart disease and cerebro-vascular accidents were 
respectively 59% and 52% higher in RA subjects than in the general 
population (Figure 1).[13] In line with these data, in a prospective study, the 
3-year incidence rate of fatal and non-fatal CV events was 9.0% in RA 
patients and 4.3% in the general population. In addition, a recent study 
showed that non-diabetic RA patients and non-RA type-2 diabetics have a 
similar high risk of CV events as compared with healthy subjects (Hazard 
Ratios, HRs: 2.16, p=0.004 and 2.04, p=0.019, respectively).[14] RA subjects 
also exhibited a higher than normal recurrence of CV events than control 
subjects (57.5% vs 30%, p=0.013). Interestingly, while chest pain at 
presentation was referred by all controls, it was found in only 82% RA 
patients (p=0.006).[15] Accordingly, RA patients were twice as likely to 
experience unrecognized myocardial infarction (HR: 2.13, 95%CI:1.13-4.03) 
and sudden death (HR: 1.94, 95%CI: 1.06-3.55) as controls.[16] In keeping 
with these findings, post-mortem evaluations of the coronary arteries of RA 
patients, showed histological evidence of a higher than normal inflammation 
and of plaque instability as compared with controls.[17] 
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Figure 1. Meta-analysis of 24 studies on cardiovascular disease 
mortality in patients with rheumatoid arthritis. 
 
Adapted from Aviña-Zubieta JA et al. Risk of cardiovascular mortality in patients with 
rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008 
Dec 15;59(12):1690-7. 
 
 
When evaluating CV risk factors, the metabolic syndrome was found in 40-
45% of AR patients[18], with dyslipidemia (defined as an abnormal ratio in the 
lipid particles leading to an unfavorable atherogenic index), being present in 
up to 50% of patients.[19,20] Overall, compared with controls, patients with 
active RA show an abnormally high prevalence of several CV risk markers.[21]  
Carotid intima-media thickness (IMT) assessment is a non-invasive imaging 
test for subclinical atherosclerosis,[22,23] and it has been widely accepted as 
one of the strongest predictors of major CV events (stroke, myocardial 
infarction, heart failure, or CV death).[24,25] The presence of carotid plaques is 
considered an even more reliable predictor of CV events than IMT. [26] Thus, 
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these surrogate markers of subclinical atherosclerosis provide important 
prognostic information over and above traditional CV risk factors. 
In a recent meta-analysis[27] we have evaluated the impact of RA on common 
carotid artery intima-media thickness (CCA-IMT) and on the prevalence of 
carotid plaques. A total of 59 studies (4,317 RA patients and 3,606 controls) 
were included in the final analysis, 51 studies with data on CCA-IMT (52 
data-sets on 3,600 RA patients and 3,020 controls) and 35 studies reporting 
on the prevalence of carotid plaques (2,859 RA patients and 2,303 controls). 
As compared to controls, RA patients showed a higher CCA-IMT (mean 
difference [MD]: 0.10 mm; 95%CI: 0.07, 0.12; P <0.00001), and an increased 
prevalence of carotid plaques (Odds Ratio [OR]: 3.61; 95%CI: 2.65, 4.93; 
P<0.001). Interestingly, when analyzing studies on early-RA, the difference in 
CCA-IMT among RA patients and controls was even higher (MD: 0.21 mm; 
95%CI: 0.06, 0.35; P=0.006), and difference in the prevalence of carotid 
plaques was entirely confirmed (OR: 3.57; 95%CI: 1.69, 7.51; P=0.0008).  
Moreover, meta-regression models (Figure 2) showed that male gender 
(Z=4.38; P=0.00001) and a more severe inflammatory status (as expressed 
by DAS-28, CRP levels, and ESR) significantly impacted on CCA-IMT (Z=2.95; 
P=0.003; Z=2.19; P=0.02 and Z=2.88; P=0.003, respectively). 
In addition, we have recently demonstrated an impaired endothelial function 
- as expressed by flow-mediated dilation and nitrate-mediated dilation - in 
patients with RA[manuscript uder review]. In a total of 20 studies (852 RA 
patients, 836 controls), RA patients showed a significantly lower FMD (MD: -
2.16%; 95%CI: -3.33, -0.98; P=0.0003), with no differences in NMD (MD: -
0.41%; 95%CI: -2.89, 2.06; P=0.74). Interestingly, a lower FMD (MD: -2.00%; 
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95%CI: -3.20, -0.80; P=0.001) and no differences in NMD (p=0.49) were 
confirmed when excluding data on patients with early-RA. Meta-regression 
models showed that no clinical or demographic variable influenced the 
association between RA and FMD.  
As to arterial stiffness, some data already suggest that RA patients show an 
arterial stiffness similar to patients with smoking habit, hypertension or 
diabetes.[28,29] 
 
Figure 2. Meta-regression analyses. Effects of male gender (Panel A), 
DAS28 (Panel B), CRP (Panel C), ESR (Panel D) on the common carotid 
artery intima-media thickness (IMT) in patients with rheumatoid 
arthritis (RA). 
 
DAS-28: disease activity score in 28 joints. CRP: C-reactive protein. ESR: erythrocyte 
sedimentation rate. 
8 
 
THE CARDIOVASCULAR RISK IN PATIENTS WITH PSORIATIC ARTHRITIS 
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy affecting up to 
40% of patients with psoriasis and leading to severe physical limitations and 
disability[30]. With a prevalence of 0.3-1% in the general population, PsA is 
one of the most common chronic inflammatory conditions[31]. Beyond skin 
and joint involvement, PsA is characterized by a high prevalence of 
comorbidities, such as autoimmune, infectious, and neoplastic diseases 
[32,33,34]. Moreover, metabolic syndrome (MetS) and its major features 
(obesity, hypertension, impaired fasting glucose, hyperlipidemia) have been 
frequently found in PsA patients,[35] and a shortened life expectancy was 
reported in this clinical setting, with CV disease accounting for up to 36% of 
the overall mortality.[36] Growing evidence on CV morbidity and mortality in 
PsA patients (Table 1) suggests that a 62% increased mortality has been 
reported in PsA subjects compared with the general population. An increased 
standardized prevalence ratios (SPR) for myocardial infarction (2.57; 95% 
CI: 1.73-3.80) and for angina (1.97; 95%CI: 1.24-3.12]) but not for stroke and 
heart failure has been prospectively reported in 648 PsA patients compared 
with nearly 40,000 controls.[37] More recently, Jamnitski et al[38] showed that 
the prevalence of CVD was 10% in patients with PsA compared with 12% in 
patients with RA (p=0.264), suggesting that the CV risk profile of PsA subjects 
resembles that of RA. Two reports[39,40] failed to show an increased risk of 
death in PsA patients as compared with healthy controls. As both were 
community-based rather than clinic-based studies, this finding may suggest a 
relationship between disease severity and mortality, as patients with the 
most severe disease activity are seen at specialized referral centers. 
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Table 1. Studies on cardiovascular morbidity and mortality in patients 
with psoriatic arthritis.  
Author Study design Controls PsA 
patients 
Overall risk Adjusted 
risk 
Myocardial infarction 
Gladman Prospective cohort 
Outpatients  
General 
population 
648 SPR:  
2.57 
- 
Li Prospective/retrospective 
cohort 
Outpatients 
93,545 2463 HR:  
7.4 
HR:  
4.18 
Coronary artery disease 
Han Cross-sectional 
Inpatients/outpatients 
12,264 3066 PREVALENCE: 
 1.3 
- 
Gladman Prospective cohort 
Outpatients 
General 
population 
648 SPR:  
1.97 
- 
Sommer Retrospective case-
control 
Inpatients  
1,044 581 PREVALENCE: 
3.6% vs 5.5% 
OR:  
1.51 
Stroke 
Han Cross-sectional 
Outpatients 
12,264 3066 PREVALENCE:  
1.3 
- 
Gladman Prospective cohort 
Outpatients  
General 
population 
648 SPR:  
0.91 
- 
Li Prospective/retrospective 
cohort 
Outpatients 
93,545 2463 HR:  
3.18 
HR:  
2.40 
Cardiovascular events 
Alhehoff Prospective cohort 
Inpatients/outpatients 
4,003,265 607 - RR:  
1.79 
Jamnitsky Cross-sectional 353 RA 489 OR:  
0.79 
- 
Peripheral arterial disease 
Han Cross-sectional 
Outpatients  
12,264 3066 PREVALENCE:  
1.6 
- 
Cardiovascular mortality 
Wong Prospective cohort 
Outpatients  
General 
population 
428 SMR:  
1.33 
- 
Buckley Retrospective cohort General 
population 
453 SMR:  
0.81 
- 
Alhehoff Prospective cohort 
Inpatients/outpatients 
4,003,265 607 - RR:  
1.84 
Mok Cross-sectional 
Inpatients/outpatients 
General 
population 
778 - SMR:  
1.59 
HR, hazard ratio; 95% CI, 95% confidence interval; OR, odds ratio; PsA, psoriatic arthritis; 
RR, relative risk; SPR: standardized prevalence ratio  
 
Adapted from Horreau C et al. Cardiovascular morbidity and mortality in psoriasis and 
psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013 
Aug;27 Suppl 3:12-29.  
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By assessing cardiovascular risk factors, PsA patients exhibit an increased 
prevalence of MetS as compared to both subjects with AR or with AS, (38% vs 
20% and vs 11%, respectively).[41] Similarly, an increased prevalence of 
hypertension, hyperlipidemia, obesity and type II diabetes (Odds Ratios 
ranging from 1.54 to 2.59) has been found in PsA subjects as compared with 
those with psoriasis.[42] As to additional VRFs, hyperhomocysteinemia may 
be caused by medications (methotrexate and salazopyrine) often used in the 
treatment of arthritides[43,44] as much as by genetic and/or nutritional 
defects. Although many literature data support the possibility of an increased 
CV risk in PsA patients, the presence of traditional CV risk factors does not 
entirely explain the CV morbidity and mortality found in this clinical setting, 
inflammation appearing to act synergistically with traditional CV risk factors, 
thus contributing to the atherosclerotic process and to the increased CV risk. 
Furthermore, scores currently used for the prediction of CV risk in the 
general population (e.g. the Framingham score; the Systematic Coronary Risk 
Evaluation model),[45,46] do not take into account the potential role of 
inflammation.[47] Based on standard algorithms, the European League Against 
Rheumatism (EULAR)[1] suggested the application of a 1.5 multiplier to the 
risk calculated in rheumatic patients. While appealing for its simplicity, this 
approach requires a long-term validation in which repeated CV risk 
assessments in rheumatologic settings are mandatory.[1] In the meanwhile, 
EULAR suggested the need of studies evaluating the intimate mechanisms of 
the interaction between inflammation and the CV risk.  
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RESEARCH PROPOSAL 
The primary aim of this project was to evaluate primary and secondary 
haemostatic parameters, as well as surrogate markers of atherosclerosis in 
PsA patients to understand underlying mechanisms leading to the increased 
CV risk in this clinical setting. To this end, and to further support the 
cooperation among experts in Rheumatology, Internal Medicine and 
Cardiology, we founded the CaRRDs (Cardiovascular Risk in Rheumatic 
Diseases) study group.  
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HAEMOSTATIC AND FIBRINOLYTIC PARAMETERS  
Primary haemostasis (platelet activation/aggregation)  
Platelet hyper-reactivity is a major predictor of arterial thrombosis and, in 
turn, of CV events.[48,49] Platelets produce inflammatory mediators (i.e. 
CD40L, myeloid-related proteins, and platelet-derived growth factor) and 
mediate leukocyte incorporation into plaques through platelet-mediated 
leukocyte adhesion. On the other hand, several cytokines/chemokines 
involved in PsA, by interacting with specific platelet receptors, cause 
intracellular calcium mobilization, nucleotide secretion and platelet 
activation.[50,51] These data suggest a synergism between inflammation and 
atherothrombosis.[52] However, little is known about the association of 
disease activity and platelet reactivity in PsA subjects receiving TNF-α 
blockers. In our study,[53] among those referred to the Psoriatic Arthritis 
Clinic of the Federico II University of Naples, we enrolled 114 consecutive 
individuals with PsA (according to CASPAR criteria54) receiving TNF-α 
blockers for ≥1 year. Healthy individuals (n=114) matched for age, gender 
and cardiovascular risk factors[55] served as controls. The achievement of a 
sustained (>1 year) minimal disease activity (MDA, according to Coates 
criteria56) was evaluated in each PsA subject. Platelet aggregability was 
evaluated by the assessment of the maximal light transmittance (max-A%) 
achieved within 5 min after the addition of very low concentrations of pro-
aggregating agents (0.1 and 0.2 mM arachidonic acid [AA] or of 0.4 µM of 
adenosine diphosphate [ADP]).[57] The achievement of an irreversible light 
transmittance ≥50% (LT-50%) defined the platelet hyper-reactivity.[58] Major 
characteristics of case and control subjects are reported in Table 2.  
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Table 2. baseline clinical and demographic characteristics of the study 
population. 
 
 
No PsA subject was receiving traditional DMARDs. Adalimumab was 
employed in 44 (35.6%) subjects; Etanercept and Infliximab in 35 (30.7%) 
each. PsA subjects achieved more often LT-50% than controls following 
exposure to 0.4 µM ADP (33.3% vs 14.0%, p=0.001), 0.1 mM AA (33.3% vs 
10.5%, p<0.001) or 0.2 mM AA (68.4% vs 19.3%, p<0.001). In addition, max-
A% was higher in PsA subjects than in controls (AA 0.1 mM: 54.50±16.10 vs 
45.28±10.93, p<0.001; AA 0.2mM: 68.14±18.45 vs 48.32±11.79, p<0.001; 
ADP 0.4µM: 51.15±20.68 vs 36.49±14.49, p<0.001). The rate of LT-50% 
achievement in the 40 PsA subjects in MDA was comparable to that of 
controls and significantly lower than that of subjects with an active disease 
(Figure 3, left side). Likewise, max-A% of those achieving MDA was 
comparable to controls and lower than that of individuals with active disease 
(Figure 3, right side).  
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Figure 3. Platelet aggregation in response to different aggregating 
agents in PsA. Relation to disease activity 
 
AA: arachidonic acid; ADP: Adenosine diphosphate; LT-50%: irreversible light 
transmittance ≥50%; MDA: minimal disease activity 
 
CRP showed a direct correlation with max-A% (AA 0.1mM: r=0.360, p<0.001; 
AA 0.2mM: r=0.278, p=0.003; ADP 0.4µM: r=0.224, p=0.018). Platelet hyper-
reactivity is a major predictor of CV events and of arterial thrombosis[48,49] 
and all our findings strongly support a synergism between inflammation and 
pathobiology of atherothrombosis.[52] Platelet reactivity is increased in PsA 
patient, especially in those with an active disease. In particular, lower 
concentrations of pro-aggregating agents were needed by PsA subjects to 
achieve LT-50% than controls and the max-A% was higher in PsA subjects 
than in controls. However, by stratifying for the disease activity, we found 
that LT-50% and max-A% of PsA subjects in MDA were comparable to 
controls and lower than PsA subjects with active disease. These findings 
confirm and extend the association between inflammation and platelet 
reactivity. The final confirmation of such an association derives by the 
evidence that CRP levels directly correlated with max-A%. 
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 Secondary haemostasis (coagulation and fibrinolysis) 
Growing evidence suggests a relevant role for changes in haemostatic system 
parameters in the determinism of the CV risk in rheumatic patients.[59] In 
addition to primary hemostasis (platelet reactivity), changes in fibrinolytic 
(t-PA, PAI-1) and secondary hemostasis variables (coagulation proteins; 
natural anticoagulants) are known to play a relevant role in the CVD risk. 
Impaired fibrinolysis and/or raised levels of coagulation factors and/or 
reduced levels of natural anticoagulants (protein C, protein S, Antithrombin) 
have been recognized as major determinants of both arterial and venous 
thrombosis.[60] By enhancing platelet reactivity and affecting a series of 
coagulation and fibrinolytic variables, pro-inflammatory cytokines (i.e. tumor 
necrosis factor-a [TNFa] and interleukin 6 [IL-6]), may trigger the thrombotic 
risk in rheumatic patients.[53,61]  
Lacking specific data on patients with PsA, we have prospectively evaluated 
changes in hemostatic and fibrinolytic variables in PsA subjects starting a 
treatment with TNF-α inhibitors.[62] In addition, we have compared changes 
in these variables with those found in subjects that had achieved minimal 
disease activity (MDA) with traditional Disease Modifying Anti-Rheumatic 
Drugs (DMARDs) and are on continuous treatment with such drugs.  
Among PsA patients screened for inclusion in the study, 76 consecutive 
subjects (40 females, 36 males; mean age: 45.7±12.3 years) that were non-
responders to the treatment with traditional DMARDs and eligible to start a 
treatment with TNF-α blockers (according to ASAS recommendations63) 
were enrolled as case group (Group 1). 
16 
 
In parallel, among those that had achieved MDA while on treatment with 
DMARDs and that were still successfully treated with such drugs at the time 
of the evaluation, 80 subjects (48 females, 32 males; mean age: 46.6±11.7 
years), matched for age and sex with those of Group 1, were enrolled in this 
study to serve as control group (Group 2). In all patients, fibrinolytic 
(plasminogen activator inhibitor-1 [PAI-1], tissue plasminogen activator [t-
PA], PAI-1/t-PA ratio) and haemostatic (Fibrinogen, D-Dimer, coagulation 
factors VII, VIII and von Willebrand Factor [vWF] Protein C, Protein S and 
Antithrombin[AT]) variables were determined at enrolment (T0) and after a 
6-month follow-up (T1). Results were stratified according to treatment and 
to the disease activity (MDA or non-MDA). 
Baseline clinical and demographic characteristic of Group 1 and Group 2 
subjects are reported in Table 3. Most of the analyzed variables were 
significantly lower in Group 2 (MDA) than in Group 1 (non-MDA) subjects. 
Table 3. baseline clinical and demographic characteristics of the study 
population. 
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During the 6-month treatment period with TNF-α blockers, 27 (35.5%) of the 
76 subjects enrolled in the Group 1 achieved MDA. All the Group 2 subjects 
were continuatively in MDA during the same time period. Figure 4 shows 
that, whereas no significant changes in ESR, CRP, haemostatic and fibrinolytic 
variables occurred in the Group 2, during the 6-months treatment with TNF-
α blockers, both ESR and CRP significantly changed in Group 1. Haemostatic 
and fibrinolytic variables changed in a similar manner.  
Figure 4. Changes in haemostatic and fibrinolytic parameters during the 
6-month follow-up. 
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In particular, Δ%PAI (r=0.326, p=0.004), Δ%PAI-1/t-PA ratio (r=0.283, 
p=0.013), Δ%DD (r=0.250, p=0.029) showed a direct significant correlation 
with Δ%CRP in the Group 1 subjects, but not in those of the Group 2.  
By stratifying the Group 1 population according to the achieving of MDA, Δ% 
of haemostatic and fibrinolytic variables levels were significantly higher in 
those achieving MDA than in those that did not (Figure 5).  
Figure 5. % changes from baseline to T1 in patients receiving TNF-α 
blockers stratified according to Minimal disease activity (MDA) 
achievement.  
 
 
To address the relationship between inflammation and changes in 
haemostatic and fibrinolytic variables, when the Group 1 population was 
stratified according to Δ%CRP tertiles, progressively higher Δ% changes in 
haemostatic and fibrinolytic variables were found for increasing Δ%CRP 
tertiles (Figure 6). Further refining these results, in a linear regression 
model, after adjusting for all the other variables, Δ%CRP significantly 
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predicted changes in PAI-1 (β=0.691, p<0.001), in t-PA (β=0.326, p=0.004) 
and in D-Dimer (β=0.233, p = 0.008). 
These same multivariate analysis, performed in Group 2 patients, did not 
retrieve any significant result.  
Figure 6. % changes in haemostatic and fibrinolytic variables in 
patients receiving TNF-α blockers stratified according to C-reactive 
protein tertiles. 
 
In multiple linear regression analyses on the whole study sample (Group 1 
and Group 2), the treatment with TNF-alpha blockers determined 
significantly higher changes in haemostatic and fibrinolytic variables as 
compared to those found in subjects continuatively treated with traditional 
DMARDs (Figure 7, Panel A).  
Specifically analyzing subjects receiving a treatment with TNF-alpha blockers 
(Group 1), the MDA achievement was a predictor of higher changes in 
haemostatic and fibrinolytic variables as compared with no-MDA status 
(Figure 7, Panel B).    
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Figure 7. Multivariate analysis for the prediction of changes in 
haemostatic and fibrinolytic variables. Panel A: Effect of the treatment 
with TNF-alpha blockers versus traditional DMARDs in the whole study 
sample (Group 1 and Group 2). Panel B: Effect of Minimal Disease 
Activity (MDA) achievement versus no-MDA status in subjects receiving 
a treatment with TNF-alpha blockers (Group 1). 
 
 
Overall, results of these multivariate analyses showed that a 6-month 
treatment with TNF-alpha blockers impacted on fibrinolysis parameters 
(PAI-1 and t-PA) as well as on some acute phase proteins (D-Dimer, FVIII and 
vWF). In contrast, the MDA achievement during treatment with TNF-alpha 
blockers maximally impacted on fibrinolytic parameters (PAI-1 and t-PA).  
Of interest, same results were confirmed when analyzing standardized β 
values. 
Results of this prospective study provide further evidence about the link 
between inflammation and thrombotic risk. In particular, we documented 
that the control of the inflammatory process is associated with a significant 
improvement of haemostatic and fibrinolytic parameters in PsA subjects, 
maximal changes being documented in patients achieving MDA. These 
variables have been found to predict arterial and venous thrombosis, that are 
major complications in PsA.[64] Previous studies have already shown that the 
overproduction of pro-inflammatory cytokines (TNF-α, IL-6), besides playing 
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a crucial role in the inflammatory process correlated with rheumatic disease 
activity,[65] it is also involved in the modulation of the fibrinolytic system.[66]  
The total fibrinolytic potential of human blood is determined by the balance  
between plasminogen activators (t-PA) and plasminogen activator inhibitors 
(PAI-1).[66] TNF-α has proved to be a potent agonist of PAI-1 expression and 
regulation.[67] In addition, high plasma levels of prothrombin fragment 1+2 
(F1 + 2) and of D-dimer (markers of thrombin activation and of fibrinolysis, 
respectively) have also been found in RA patients.[68] Thus, by inducing a pro-
coagulant shift in the haemostatic balance, chronic inflammation promotes 
fibrin generation and, in turn, thrombosis.[69,70] 
At variance with all the other previous studies, exclusively focused on RA 
patients, we have extended the evaluation of global haemostasis changes to 
PsA patients.  
In addition, besides the evaluation of fibrinolytic balance, in this study we 
reported about changes in a series of other hemostatic factors. In detail, vWF, 
FVIII and FVII are recognized acute phase proteins, increasing in the 
presence of inflammation, cancer and pregnancy[71] and leading to a 
prothrombotic state and to an increased risk of venous and arterial 
thrombosis.[72] Moreover, Prot. C and Prot. S are natural anticoagulant 
proteins that play a major role in opposing hypercoagulable states.[73] 
Consistent with the link between natural anticoagulants and variables 
involved in hypercoagulable states, changes we have reported in Prot. C and 
Prot. S levels are likely to be related to the changes that occurred in PAI-1 
and t-PA levels. 
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This is also the first study prospectively comparing the effects induced by 
TNF-α inhibitors and by traditional DMARDs on secondary haemostasis 
parameters. Indeed, the contemporary evaluation of a group of subjects 
continuatively treated with traditional DMARDs allowed for a comparison of 
the effects of traditional and biologic anti-rheumatic drugs on hemostatic 
parameters. 
In line with previous studies,[74] at the baseline evaluation, by assessing the 
impact of inflammation and of disease activity on haemostatic and 
fibrinolytic variables, we found that most of these parameters were 
significantly higher in patients with an active disease than in those with 
minimal disease activity. Of interest, being all subjects under DMARDs at the 
time of the baseline assessment, we are confident to have evaluated the 
impact of disease activity on haemostatic and fibrinolytic balance. 
In addition to traditional DMARDs, treatment with TNF-α inhibitors 
improved clinical and laboratory measures of disease activity in rheumatic 
diseases and reduces local and systemic inflammation. Besides the control of 
inflammation, TNF-α inhibitors have been found to down-regulate 
fibrinolytic as well as haemostatic parameters and to normalize platelet 
hyper-reactivity, thus leading to a reduction in the CV risk.[61,66,75,76]  
We have found that, at the end of the 6-month follow-up, as compared with 
those continuatively treated with DMARDs, those starting a treatment with 
TNF-α blockers, showed a significant reduction in haemostatic and 
fibrinolytic parameters. In addition, maximal changes in coagulation 
variables were found in those achieving the MDA during the TNF-α blocker 
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treatment. In keeping with this, for increasing changes in CRP levels, a 
progressively higher variation in all evaluated variables was found.  
For comparison purposes, inflammatory markers and hemostatic/fibrinolytic 
parameters did not change in the group of patients kept on receiving 
traditional DMARDs (all changes <10% from baseline).  
In addition, with the exception of AT levels, DMARDs patients had higher 
levels of haemostatic and fibrinolytic factors when compared to anti-TNF 
patients (both to those achieving MDA and to those with persistent active 
disease). These findings might suggest the possibility that the mechanism of 
action of TNF-α inhibitors on haemostatic and fibrinolytic parameters does 
not depend only from the successful control of inflammation (MDA 
achievement). However, this issue cannot be ruled out in this study and 
further data are needed to understand whether improvements obtained in 
hemostatic and fibrinolytic parameters are just correlated to reduction of 
inflammatory status. 
In conclusion, our study confirms the role of TNF-α inhibition in the 
reduction of systemic inflammation, with a significant improvement in the 
global hemostatic and fibrinolytic balance of PsA patients. These data suggest 
a potential cardio-protective effects of TNF-α inhibitors. Whether this is a 
drug-specific effect or a consequence of the inflammatory process control is 
unclear so far and cannot be ruled out based on the present data. 
Further studies evaluating risks (side effects)[77] and benefits (anti-
inflammatory and cardioprotective effects) of the treatment with TNF-α 
inhibitors are needed to allow for a tailored anti-rheumatic treatment choice.  
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SURROGATE MARKERS OF ATHEROSCLEROSIS 
Sub-clinical atherosclerosis: Carotid intima-media thickness  
Carotid intima-media thickness (IMT) assessment is a non-invasive imaging 
test for subclinical atherosclerosis,[22,23] and it has been widely accepted as 
one of the strongest predictors of major CV events (stroke, myocardial 
infarction, heart failure, or CV death).[24,25] The presence of carotid plaques is 
considered an even more reliable predictor of CV events than IMT.[26] Thus, 
these surrogate markers of subclinical atherosclerosis provide important 
prognostic information over and above traditional CV risk factors. Some 
functional and ultrasonographic assessments support the evidence of an 
increased CV risk profile in PsA patients. In a cohort study, PsA patients 
showed an higher carotid IMT than controls (0.76±0.11 vs 0.64±0.27, 
p<0.001).[78] To avoid potential confounders, Gonzalez-Juanatey et al studied 
a population of PsA subjects without established VRFs. Compared with 
matched controls, an impaired endothelium-dependent vasodilation 
(p=0.008) and a higher IMT (p=0.031) were found in the PsA group.[79,80] 
Consistent with data showing a correlation between inflammation and 
IMT,[60,81] an association between disease activity in PsA and the presence of 
carotid plaques has been reported.[82]  
With the aim to provide a pooled analysis on the topic of sub-clinical 
atherosclerosis in PsA patients, we performed a systematic review and meta-
analysis of literature studies.[83] In 12 studies (13 data-sets on 759 cases and 
937 controls), we found a significantly higher CCA-IMT in 759 PsA patients 
than in 937 controls (MD: 0.07 mm; 95%CI: 0.04, 0.11; P <0.0001, Figure 8). 
The heterogeneity among studies was significant (I2=75%; P<0.00001) but, 
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after excluding one study, similar results were obtained without 
heterogeneity (MD: 0.08 mm; 95%CI: 0.07, 0.10; P <0.00001, I2=2%; 
P<0.00001).  
Figure 8. Common carotid artery intima-media thickness (CCA-IMT) in 
psoriatic arthritis (PsA) patients and controls. 
 
 
A total of 9 studies (10 data-sets on 648 cases and 787 controls), showed an 
increased prevalence of carotid plaques in 648 PsA patients as compared to 
787 controls (28.3% vs 10.9%), with a corresponding OR of 3.12 (95%CI: 
1.03, 9.39; P=0.04, Figure 9). Significant heterogeneity among studies was 
found (I2=91%; P<0.00001). Of interest, after excluding one study, we found 
similar results without heterogeneity (OR: 3.51; 95%CI: 2.33, 5.29; P 
<0.00001, I2=0%; P=0.67).  
Figure 9. Prevalence of carotid plaques in psoriatic arthritis (PsA) 
patients and controls. 
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With the aim to evaluate effects of different treatments on IMT, we 
performed a case-control study[76] on 224 PsA patients (120 on TNF-α 
blockers and 104 on traditional Disease Modifying Anti-Rheumatic Drugs 
[DMARDs]) that  underwent a CCA-IMT ultrasound assessment. As many as 
305 matched subjects without any inflammatory/rheumatologic disease, 
served as controls. As shown in Table 4, PsA subjects without VRFs had a 
CCA-IMT (mean-maxCCA and mean-maxBulb) significantly higher than that of 
control subjects. Among those with 1-3 risk factors, the CCA-IMT of PsA 
subjects was significantly lower than that of controls, while in subjects with 
≥3 VRFs, no significant difference was present between PsA and control 
subjects. 
Table 4. Intima-media thickness (CCA and Bulb) in subjects with 
psoriatic arthritis (PsA) according to the number of vascular risk 
factors (VRFs). 
Number 
of VRFs 
mean-maxCCA (mm)  mean-maxBulb (mm) 
PsA 
N= 224 
Controls 
N= 305 
p value  PsA 
N= 224 
Controls 
N= 305 
p value 
 
0 VRF 
n= 
0.72±0.25 
20 
0.56±0.08 
24 
0.025  1.09±0.40 
20 
0.87±0.21 
24 
0.032 
1 VRF 
n= 
0.69±0.24 
60 
0.78±0.14 
67 
0.001  0.96±0.44 
60 
1.24±0.34 
67 
<0.0001 
2 VRF 
n= 
0.70±0.17 
52 
0.78±0.19 
90 
0.006  1.02±0.50 
52 
1.29±0.41 
90 
<0.0001 
3 VRF 
n= 
0.75±0.15 
44 
0.86±0.31 
74 
0.040  1.09±0.35 
44 
1.37±0.45 
74 
<0.0001 
4 VRF 
n= 
0.88±0.25 
44 
0.88±0.31 
39 
0.833  1.25±0.43 
44 
1.39±0.43 
39 
0.126 
5 VRF 
n= 
0.91±0.13 
4 
0.96±0.19 
11 
0.720  1.37±0.65 
4 
1.42±0.37 
11 
0.633 
Note: all p are for log-transformed values of CCA and Bulb; VRFs: vascular risk factors; 
N= number of subjects; CCA: common carotid artery 
 
As showed in Table 5, PsA subjects on TNF-α blockers and those on 
traditional DMARDs significantly differed as to CCA-IMT measurements. 
Accordingly, carotid plaques were found in 15.8% of subjects on TNF-α 
blockers and in 40.4% of subjects on traditional DMARDs (p<0.0001).  
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Table 5. Demographic and clinical features of the study population 
(Panel A) and stratification according to treatment schedules (Panel B). 
Variable PsA  subjects 
on TNF-α blockers 
n=120 
PsA subjects 
on DMARDs 
n=104 
p 
Age 51.5±10.9 53.8±11.9 0.120 
Male sex 56 (46.7%) 48 (46.2%) 1.000 
MetS 36(30.0%) 40 (38.5%) 0.204 
IFG 12(10.0%) 8(7.7%) 0.642 
Hypertension 48(40.0%) 44(42.3%) 0.786 
Hypercholesterolemia  68(56.7%) 48(46.2%) 0.140 
Hypertriglyceridemia 28(23.3%) 32(30.8%) 0.229 
Obesity 76(63.3%) 64(61.5%) 0.784 
Smoking habit 36(30%) 28(26.9%) 0.658 
Disease duration (months) 113.62±58.24 103.79±85.91 0.312 
Treatment characteristics    
Treatment duration (months) 52.33±24.11 58.22±29.21 0.100 
Disease activity    
Low disease activity 88 (73.3) 30(28.8) 0.001 
ESR (mm) 14.23±8.53 24.11±16.66 <0.0001 
CRP mg/dl 1.98±1.8 3.6±3.9 0.007 
IL-6 (ng/L) 3.9±0.6 5.0 ± 0.8 0.07 
Ultrasound evaluation    
mean-maxCCA  (mm) 0.70±0.18 0.80±0.26 0.002 
mean-maxBulb (mm) 0.94±0.31 1.24±0.52 <0.001 
Carotid plaques n(%) 19(15.8%) 42(40.4%) <0.0001 
 
The mean-maxBulb showed a direct correlation with treatment (r=0.321, 
p=0.001) and with disease (r=0.392, p<0.001) duration in those on 
traditional DMARDs (Figure 10). In the same group, mean-maxCCA showed a 
direct correlation with disease duration (r=0.203, p=0.039). In keeping with 
this, subjects with ultrasound evidence of carotid plaques had a disease 
duration significantly longer than that of subjects without (130.34±106.75 vs 
101.09±52.56, p=0.007). No correlation with treatment duration was 
documented in PsA subjects on DMARDs when the mean-maxCCA was examined. 
In those on TNF-α blockers, whereas no significant correlation was found 
between disease duration and C-IMT (mean-maxCCA: r=-0.005, p=0.954; mean-
maxBulb: r=0.011, p=0.904), a significant inverse correlation between 
treatment duration and C-IMT was found (mean-maxCCA: r=-0.319, p<0.001; 
mean-maxBulb: r=-0.296, p=0.001). The presence of carotid plaques inversely 
correlated with treatment duration (r=-0.206, p=0.024), and did not show a 
significant correlation (r=0.014,p=0.877) with disease duration. 
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Figure 10. Scatter plot of Pearson’s correlations between C-IMT (mm) 
and treatment duration (months). A, TNF-α blocker group. B, 
Traditional DMARDs group. All P values are for log-transformed values 
of CCA and bulb. 
 
In a linear regression model, age (β=0.382, p<0.0001), male sex (β=0.134, 
p=0.009), treatment with traditional DMARDs (β=0.202, p=0.001) and 
clinical remission (β=-0.236, p<0.0001) independently predicted the CCA-
IMT (whole PsA sample). Among VRFs, hypertension (β=0.221, p<0.0001) 
independently predicted the C-IMT in this setting as did the number of VRFs 
(β=0.225, p<0.0001). 
When the patient population was stratified according to treatment schedules, 
whereas age predicted CCA-IMT both in the DMARDs group (β=0.371, 
p<0.0001) and in the TNF-α-blockers group (β=0.302, p<0.0001), ESR levels 
directly predicted CCA-IMT (β=0.254, p=0.001) in PsA subjects on DMARDs, 
but not in those on TNF-α blockers. In keeping with this, arterial 
hypertension predicted the C-IMT only in subjects on DMARDs treatment 
(β=0.646, p<0.0001). On the other hand, treatment duration significantly and 
independently (β=-0.317, p<0.0001) predicted the CCA-IMT in those on TNF-
α blockers, but not in those on traditional DMARDs.  
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The vascular reactivity: Flow-mediated and Nitrate-mediated dilation  
Flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) are 
considered surrogate markers of subclinical atherosclerosis and independent 
predictors of CV events,[84] thus providing important prognostic data over 
and above traditional CV risk factors.  
In the frame of our project, we have performed a meta-analysis[83] in which 
we pooled together 6 studies (7 data-sets on 229 PsA patients and 279 
controls), showing a significantly lower FMD in PsA subjects as compared to 
controls (MD: -2.56%; 95%CI: -4.17, -0.94; P=0.002, Figure 11).  
Flow 11 mediated-dilation (FMD) in psoriatic arthritis (PsA) patients 
and controls. 
 
 
 
In contrast, no difference in the NMD was found in 4 studies (5 data-sets on 
173 cases and 192 controls) with a MD of -0.40% (95%CI: -1.19, 0.39, P=0.32, 
Figure 12).  
Figure 12. Nitrate mediated-dilation (NMD) in psoriatic arthritis (PsA) 
patients and controls 
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Our results consistently show that PsA is associated with subclinical 
atherosclerosis and endothelial dysfunction. In particular, we demonstrated 
an increased carotid CCA-IMT with a high prevalence of carotid plaques and 
impaired FMD in patients with PsA. Our findings are strengthened by meta-
regression models providing the evidence that demographic variables (age 
and gender) did not influence the impact of PsA on carotid CCA-IMT.  
Overall, these data clearly show an increased CV risk in patients with PsA and 
suggest the need for a strict monitoring of CV risk factors and of signs of 
subclinical atherosclerosis in PsA patients. Accordingly, previous published 
studies reported an increased risk of major CV events and CV death in 
patients with PsA.  
Many CV risk factors are thought to have a causal role in the atherosclerotic 
process.[85] Although PsA patients exhibit an increased prevalence of these CV 
risk factors, the relationship between subclinical atherosclerosis and PsA 
seems to be more complex and the presence of traditional risk factors might 
not entirely explain the accelerated atherosclerotic process in this clinical 
setting.[86] Thus, other mechanisms (i.e. inflammatory and immunological) 
have been proposed to explain the relationship between PsA and 
atherosclerosis and immune-mediated inflammation seems to play a pivotal 
role in the pathogenesis of atherosclerosis, being involved in endothelial 
dysfunction, plaque rupture and thrombosis.[87] In keeping with this, some 
common markers of inflammation (i.e. CRP, fibrinogen) are emerging 
predictors of CV disease,[88,89] and patients with PsA exhibit elevated levels of 
these acute-phase proteins.[90] ESR, another marker of inflammation, is 
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commonly found increased in PsA and high ESR has been associated with 
increased overall mortality in this clinical setting.[91]  
The link between inflammation and the subclinical atherosclerosis has been 
further addressed in our cross-sectional study showing that, in the absence of 
VRFs, the CCA-IMT of PsA patients is significantly higher than that of 
controls. However, when stratified according to the presence of VRFs, the 
CCA-IMT of PsA individuals is lower than those of controls. The finding that, 
in the presence of 1-3 VRFs, PsA subjects have a lower C-IMT as compared 
with controls, may be taken to suggest a protective effect of anti-
inflammatory drugs on the CCA-IMT. On the other hand, since an higher CCA-
IMT is predicted by an increasing number of VRFs in PsA subjects, an additive 
effect of VRFs can be postulated to overcome the protective effect of anti-
inflammatory drugs. However, the CCA-IMT was lower in PsA subjects on 
TNF-α blockers than in those on traditional DMARDs and the co-existence of 
a MetS was associated with an higher CCA-IMT in subjects on DMARDs than 
in those under TNF-α blockers. Over the past decade, TNF-α blockers have 
provided a significant advancement for preventing the progression of 
inflammation and of the structural damage of joints in patients with 
psoriasis, PsA, or RA.[92,93,94] In addition, TNF-α blockers improve the 
endothelial function and the vascular risk profile in patients with immune-
mediated disorders.[95] In our study, the effects elicited by TNF-α blockers 
appear to be accounted for by subtle anti-inflammatory mechanisms. ESR 
levels significantly predicted CCA-IMT only in PsA subjects on DMARDs. ESR 
and CRP were significantly lower in subjects on TNF-α blockers than in those 
on DMARDs. By inhibiting pro-inflammatory cytokines involved in insulin 
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regulation, lipid metabolism and in body weight homeostasis, TNF-α blockers 
reduce the prevalence of the MetS in subjects with rheumatologic disease.[96] 
Consistent with a large body of evidence, as much as 35-40% of the present 
PsA sample exhibited the MetS. However, at variance with subjects on 
DMARDs, the MetS was not associated with differences in CCA-IMT in 
subjects on TNF-α blockers. Accordingly, clinical remission was present in 
73.3% of subjects on TNF-α blockers and in 28.8% of those on traditional 
DMARDs. Consistent with the concept that the reduction of systemic 
inflammation may hamper the cascade that leads to enhanced vascular risk in 
PsA patients, our results documented a significantly reduced CCA-IMT in 
patients on TNF-α blockers as compared to those on DMARDs. In addition, 
our data show that, while largely independent of disease duration and 
preexisting atherogenic risk factors featuring the MetS, the efficacy of TNF-α 
blockers was related to treatment duration. This is consistent with a 
progressive effect of inflammation on the CCA-IMT. 
Overall, our findings are in line with some experimental and clinical evidence, 
supporting the hypothesis that premature atherosclerosis may be one of the 
main features of PsA and that chronic inflammation plays an important role 
in its pathogenesis, acting independently and/or synergistically with 
traditional CV risk factors. The clinical relevance of our results can be better 
understood when we consider that the risk of myocardial infarction increases 
of 43% every 0.163 mm increase in carotid IMT[97] and that the prevalence of 
carotid plaques is an even more reliable predictor of CV events than IMT.[26] 
Moreover, each 1% decrease in FMD has been associated with a 12% 
increase of cardiovascular events.[98]  
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Our results further support the need for large long-term interventional trials 
with CV end-points to investigate whether benefits in articular disease 
achieved by aggressive suppression of inflammation may translate into 
reduced CV risk in PsA. 
In the meanwhile, patients with PsA may benefit from a periodic assessment 
of surrogate markers of CV risk to establish more specific CV prevention 
strategies for these patients. 
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Conclusions and Perspectives 
Overall, results of our project suggest that PsA patients have a increased 
platelet reactivity, impaired fibrinolysis and subclinical atherosclerosis 
accompanied by an impaired endothelial function. 
Most of these alterations seem to be associated with the inflammatory status 
and are likely to be modified by the anti-rheumatic treatments.  
All these data are in line with many literature data that support the 
possibility of an increased CV risk in patients with rheumatic diseases. The 
finding that the vascular morbidity/mortality of rheumatic patients 
resembles that of type II diabetes, further helps to define the severity of the 
CV risk in this clinical setting.[14] However, the difference documented in the 
risk of CV death between community-based and clinic-based studies, argues 
for different risk according to the disease activity, only those with a severe 
disease being referred to specialized centers.[39, 40] The extent to what the 
estimate of the CV risk in rheumatic patients is likely to be biased by a 
significant under-diagnosis, and in turn by under-treatment, of concomitant 
VRFs is unknown so far and needs to be evaluated.[99]  
The increase of CV risk in patients with rheumatic diseases as compared with 
both healthy populations and VRFs-matched subjects support the notion that 
systemic inflammation acts as an independent CV risk factor.[100] The 
improvement of the CV risk profile following the control of systemic 
inflammation by anti-inflammatory treatments argues for this possibility as 
well.[101,102] While this implies that the incidence of CV morbidity/mortality 
should be re-evaluated according to an optimal inflammation control (i.e. 
achieving minimal disease activity), inflammation/disease activity has been 
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recently suggested to be included in the CV risk factor profile of such 
patients.[100] However, scores currently used for the general population (e.g. 
the Framingham score; the Systematic Coronary Risk Evaluation model),[45, 
46] do not take into account the role of inflammation.[47] Based on standard 
algorithms, the European League Against Rheumatism (EULAR)[1] suggested 
the application of a 1.5 multiplier to the risk calculated in rheumatic patients. 
While appealing for its simplicity, this approach requires a long-term 
validation in which repeated CV risk assessments in rheumatologic settings 
are mandatory.[1]  
In the meanwhile, searching to explain mechanism underlying the CV risk in 
PsA patients, we have designed a further project which has been funded by 
the Italian Ministry Health. In this prospective study we will assess, at 
different time-points, changes in the circulating transcriptome and in carotid 
CCA-IMT during treatment with TNF-alpha blockers. The main objective is to 
assess if treatment with TNF-alpha blockers may reduce CCA-IMT in patients 
with active PsA. Another major goal is to identify circulating transcriptomic 
markers associated with treatment response. Results of this study will 
provide information about the link between inflammation and subclinical 
atherosclerosis, allowing for a better definition of the CV risk profile in PsA 
patients. In addition, we will try to identify circulating markers predicting the 
minimal disease activity (MDA) achievement.  
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